It was a pleasure to speak with Camille Carroll (University of Plymouth, Plymouth, UK) about her late-breaking presentation entitled: Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): results of a double-blind, randomised, placebo-controlled futility study. ClinicalTrials.gov Identifier: NCT02787590.
Questions
- What was the scientific rationale for investigating simvastatin as a neuroprotective treatment for Parkinson’s disease (PD)? (0:06)
- Could you tell us a little about the aims and design of the PD STAT trial? (1:48)
- Did COVID-19 pose any challenge to the study? (3:25)
- What were the main findings of this study? (6:23)
- Why do you think that simvastatin was not effective in slowing the rate of progression of PD? (6:05)
- What other potentially disease-modifying agents are being investigated? (8:11)
Disclosures: Dr Carroll is the study director and reports receiving study funding from the Cure Parkinson’s Trust and JP Moulton Charitable Foundation.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.
